A large international consortium reports in Nature on the diversity of genomic changes in families with autism spectrum disorders. Inherited and de novo mutations affecting many genes were discovered implicating disruption to postsynaptic and cellular signaling processes.
Autism spectrum disorders (ASDs) embrace a combination of behavioral phenotypes impacting on cognitive, social, and motor functions. The genetic basis of ASD, originally revealed in twin and family studies, is now being investigated on a genome-wide level using recent technological advances, resulting in the discovery of a multiplicity of putative driver mutations in neuronal and neurodevelopmental genes, including postsynaptic genes [a recent issue of Nature]). Understanding how this complex genetic etiology disrupts biochemical mechanisms and influences the spectrum of behavioral phenotypes in individuals may lead to new therapeutic avenues and insights into the molecular basis of human social interactions.
With the inexorable progress toward whole genome sequencing, mutations ranging in size from a single nucleotide to deletions and insertions of contiguous regions will be measured in each and every gene for all diseases. Many rare diseases of the nervous system are caused by a mutation in single genes, and there are ''complex'' diseases that have their basis in mutations affecting many genes. Prominent among these complex diseases are ASD, schizophrenia, and bipolar disease (Carroll and Owen, 2009) . While it is only a matter of time before we have a definitive description of the genomic variation in ASD individuals using whole genome sequencing, an international consortium has reported the genomic variation at a lower resolution in individuals and families with ASD . This report, building on earlier studies, provides new evidence that changes in the function of many genes, arising by rare inherited and de novo mutations, underlie the behavioral phenotypes of ASD.
The study surveyed the genome for deletions or insertions (extra copies of genomic DNA) greater than 30 kb in size and asked if ASD cases were different to controls. These are known as copy number variants (CNV) and represent a type of chromosomal rearrangement. Since the 1920s, chromosomal architecture was visualized using DNA staining and microscopy, giving rise to the discipline of cytogenetics, an approach that led to the discovery of the genetic basis of human diseases such as chronic myelogenous leukemia and Down's syndrome. Refinements in techniques including fluorescence in situ hybridization (FISH) and oligonucleotide hybridization improved the resolution of cytogenetic assays from tens of megabases to the current levels of 20 nucleotides. Unlike FISH, oligonucleotide microarrays allow rapid, efficient, and unbiased genome-wide assays for DNA variation and have fuelled high-resolution linkage and association scans seeking to find the mutational basis of schizophrenia, bipolar disorder, and ASD Psychiatric GWAS Consortium Coordinating Committee et al., 2009) . The present study used commercial microarrays with one million synthetic oligonucleotides designed to survey all genes and chromosomal regions with representative probes. Genomic DNA from cases and controls was hybridized to the microarrays, and the intensity of the hybridization signal provided a quantification of the number of DNA copies in that part of the genome.
Why are CNVs good candidates for pathogenic variants? While polymorphisms in single nucleotides can alter protein structure and function, or influence gene regulation, the number of nucleotides affected by CNVs is much larger (Cheng et al., 2005) . CNVs are more likely to affect genes, either by insertions or deletions that interrupt protein coding regions, or change gene dosage (and thus levels of mRNA) by duplicating or deleting a copy of the gene. It is worth noting the similarity between CNVs and the favorite tools of the mouse geneticists-transgenic insertion or knockout deletion of whole genes-as both change gene dosage. Moreover, this emphasizes the relevance of mouse models as a tool to verify the functional significance of human CNVs.
Before considering how CNVs might result in disease, it is important to remember that the genome is dynamic and constantly evolving, generating variation and diversity, much of which may be without phenotypic consequences. The extent of this diversity was revealed by a catalog of 11,700 CNVs found within normal populations measured using ultra-high density oligonucleotide arrays (Conrad et al., 2010) . Investigating 3432 common CNV regions, a large-scale study of eight common diseases (including bipolar disorder) concluded that common CNVs were unlikely to account for much disease (Wellcome Trust Case Control Consortium et al., 2010) . This leaves open the possibility that rare CNVs are more pathogenic but also underlines the challenge faced in establishing the functional significance of a CNV.
Pinto and colleagues (2010) have used a family linkage study design to search the genome of ASD cases for gene disruptions by CNVs that segregate with ASD. They specifically examined those CNVs R30 kb in length that were rare (<1% of all individuals) and overlapped protein coding genes. They examined 996 ASD cases including 876 in parentoffspring trios, thus distinguishing inherited from de novo CNVs. CNVs in these trios were also compared with CNVs found in another 1287 normal controls. The average number of genes intersected by CNVs in each control individual was 3.6, giving an indication of the normal genic burden of CNVs. Their first finding was that ASD cases had 19% more affected genes (4.3 genes) than controls. This was statistically significant and stronger for deletions than insertions, suggesting that loss of function of genes is more frequent in ASD. Next, they asked whether these CNVs arose as inherited or de novo events; they found in their trios that 5.7% of cases had a de novo event, reinforcing earlier reports showing de novo mutations arise in complex neuropsychiatric disorders (Glessner et al., 2009) . This is an interesting and as yet unexplained phenomenon, which could reflect differences in mutation rate or genomic stability.
A fundamental limitation on analysis of rare and de novo variants is the rarity of these events. For example, SHANK2, SynGAP, and DLGAP2 involvements in ASD were only supported by variants in one or two cases each. Despite the lack of formal statistical significance, however, the authors cite the fact that mutations in these proteins, their interacting partners, or their paralogs have been implicated before in ASD or mental retardation (Durand et al., 2007; Hamdan et al., 2009; Romorini et al., 2004) , which helps to build the case for their relevance. As shown in Figure 1 , they highlight SHANK2, Syn-GAP1, and DLGAP2, which interact in postsynaptic complexes with MAGUK (membrane associated guanylate kinase) proteins (PSD-95/DLG4, SAP102/DLG3, PSD-93/DLG2). MAGUKs also bind glutamate receptors (NMDA, AMPA, metabotropic) and Neuroligins, which in turn bind Neurexins, among other proteins. De novo CNVs disrupting Neurexin1 exons were detected in four ASD cases. Several of these additional interacting proteins were earlier implicated in other human cognitive disorders: mental retardation (SAP102/DLG3; SynGAP), ASD (SHANK3), and schizophrenia (PSD93/DLG2, DLGAP1). Additional support for the functional relevance of CNVs in these proteins comes from the observation that cognition is altered in knockout mouse models of SynGAP, SHANK1, and DLGAP3.
One of the attractions of a model where rare mutations affect different proteins in the same multiprotein complex is that although a particular gene may be disrupted by only one CNV in a whole study, and thus fail to reach statistical significance, independent mutations in functionally interacting subsets of brain proteins may yet point the way to a biochemical mechanism for the disease. In addition, varying phenotypes due to mutations of different interacting proteins can help define the genetic underpinnings of the ''spectrum'' of related phenotypes. A detailed study of the specific endophenotypes of individuals with the mutations in SynGAP, SHANK, and DLGAP2 and other interacting proteins may shed light on the molecular basis of these ASD endophenotypes and their relationship to schizophrenia and other diseases.
Although there is accumulating and compelling evidence that ASDs involve postsynaptic complexes, inspection of genic content of other de novo events reveals putative disruption of proteins found in the nucleus: NFIA is a transcriptional activator; CHD2 is a sequenceselective DNA binding helicase; RBL2 maintains chromatin configuration. It may be that ASD involves both nuclear and synaptic pathology due to some functional interconnection between these proteins.
Another approach to the data was an enrichment analysis of rare variants with respect to several short gene lists constructed from the studies of others. This approach was useful, because it groups variants that by themselves are insignificantly associated with the disease and answer the question: are these data in agreement with those of others? One such list the authors used was an ''autism implicated'' list containing the 46 best candidate regions so far identified by others: 4.3% of cases in the present study had rare CNVs impacting genes in this list, compared to 2.3% of controls. Even though this may seem like a small proportion of the cases, it may be an underestimate resulting from limitations in the microarray method, which future resequencing of these genes will clarify.
In an attempt to find known biochemical pathways or processes targeted by the CNVs, a gene set enrichment analysis was also performed using gene sets compiled from the Gene Ontology, KEGG pathways, and other sources. Among 3493 gene-sets tested, only 76 exhibited enrichment, and then only in deletions, suggesting as before that deletions are more likely to cause functional disruption than insertions. Enriched sets included kinase activity, GTPase/Ras signaling, cell proliferation, cell projection, and motility, which generally point to signal transduction and growth related processes. Interestingly, although the tested gene sets included neurotransmitters and their receptors, these were not enriched by the ASD CNVs, suggesting ASD is less a disorder of neurotransmitters and more a disorder of intracellular signaling processes.
Complex genetic disorders of the nervous system pose a range of special problems, some of which are illustrated by this study, and we believe will require new approaches. The fact that many genomic changes underpin ASD, schizophrenia, bipolar, and other complex genetic disorders, illustrates the need for research strategies that emphasize the function of sets of genes. The involvement of sets of genes in biochemical machines, such as postsynaptic signaling complexes (Ferná ndez et al., 2009) or networks (Pocklington et al., 2006) may reduce the statistical complexity of these investigations and offer clues to the underlying etiology of these diseases. How these networks are altered by the range of mutations could be tested with suitable model systems, which will always need to include behavioral models since the diseases manifest as social, cognitive, and motoric changes. In this regard, we see a need for programs of systematic analysis of mouse models in specific and relevant psychological tests that are coordinated with human genetic studies and genome sequencing. As indicated by Pinto et al. (2010) , it will be essential to ask if specific components within the spectrum of autism phenotypes map onto specific genotypes; an endeavor that will require coordinated efforts of clinicians and geneticists. The scale of the genetic complexity, the need to coordinate human genetic studies with mouse genetic models and the need to coordinate clinical studies with genome sequencing suggests that ASD, as well as schizophrenia, bipolar, and other complex diseases, would greatly benefit from coordinated large scale international research programs.
